Drug intelligence / Profile preview

AG-86893

Development stage: Phase 2
Lead developer: Allgenesis Biotherapeutics
Modality: Small Molecules
Administration: Ophthalmic

Overview

AG-86893 is a kinase inhibitor being developed as an ophthalmic formulation for ocular surface neovascularization. It is a reformulation of nintedanib, targeting receptor tyrosine kinases (RTKs) to inhibit new blood vessel growth and fibrosis that may contribute to pterygium growth. The drug is administered as eye drops and has been studied for treating pterygium hyperemia (redness) and growth.

Targets

RTK (Receptor Tyrosine Kinase)

Beyond the preview

Go deeper on AG-86893.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AG-86893.

Explore the full profile